April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Ranibizumab Intravitreal Injection for Myopic Choroidal Neovascularization
Author Affiliations & Notes
  • Joao J. Nassaralla, Jr.
    Retina and Vitreous, Instituto de Olhos de Goiania and UnB, Goiania, Brazil
  • Belquiz A. Nassaralla
    Cataract, Cornea and Refractive Surgery, Instituto de Olhos de Goiania, Goiania, Brazil
  • Footnotes
    Commercial Relationships  Joao J. Nassaralla, Jr., None; Belquiz A. Nassaralla, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4509. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao J. Nassaralla, Jr., Belquiz A. Nassaralla; Ranibizumab Intravitreal Injection for Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4509.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the clinical results of ranibizumab intravitreal injection (RII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV).


30 patients with subfoveal PM-CNV, were treated with of 0,5 mg ( 0.05mL) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. RII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 1 year.


The mean age of the study patients was 32 years (25-48) and the mean refractive error -11.50 D. At 12 months post-treatment, mean VA increased from 20/100 (20/400 -20/40) to 20/50 (20/200-20/30). Only 3 patients lost 35 letters due to macular atrophy; the other 27 increased or stabilized their VA. Mean macular thickness decreased from 329 to 258 µm. No ocular or general side effects were recorded.


These short-term results suggest that RII are effective and safe in patients with PM-CNV. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Clinical Trial:

http://www.clinicaltrials.gov NCT01246089

Keywords: myopia • retinal neovascularization • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.